Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* MCKEON BRIAN P	2. Issuer Name and Ticker or Trading Symbol IDEXX LABORATORIES INC /DE [ IDXX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Executive VP & CFO
(Last) (First) (Middle) ONE IDEXX DRIVE	3. Date of Earliest Transaction (MM/DD/YYYY) 11/4/2020
(Street) WESTBROOK, ME 04092 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/4/2020		M		36216	A	$79.54	60916 ⁽¹⁾	D
Common Stock	11/4/2020		S		1400	D	$467.0142 ⁽²⁾	59516	D
Common Stock	11/4/2020		S		6338	D	$467.9662 ⁽³⁾	53178	D
Common Stock	11/4/2020		S		9617	D	$469.0944 ⁽⁴⁾	43561	D
Common Stock	11/4/2020		S		2850	D	$469.7968 ⁽⁵⁾	40711	D
Common Stock	11/4/2020		S		2493	D	$471.0224 ⁽⁶⁾	38218	D
Common Stock	11/4/2020		S		1107	D	$472.1960 ⁽⁷⁾	37111	D
Common Stock	11/4/2020		S		2407	D	$473.0377 ⁽⁸⁾	34704	D
Common Stock	11/4/2020		S		244	D	$473.9679 ⁽⁹⁾	34460	D
Common Stock	11/4/2020		S		3474	D	$475.2004 ⁽¹⁰⁾	30986	D
Common Stock	11/4/2020		S		3596	D	$476.0122 ⁽¹¹⁾	27390	D
Common Stock	11/4/2020		S		390	D	$477.0165 ⁽¹²⁾	27000	D
Common Stock	11/4/2020		S		1534	D	$479.6945 ⁽¹³⁾	25466	D
Common Stock	11/4/2020		S		566	D	$480.3068 ⁽¹⁴⁾	24900	D
Common Stock	11/4/2020		S		200	D	$481.26	24700	D
Common Stock								28050	I	by Estony McKeon Family, LLC

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right-to-buy)	$79.54	11/4/2020		M			36216	⁽¹⁵⁾	2/13/2025	Common Stock	36216	⁽¹⁶⁾	0	D

Explanation of Responses:
(1)	Includes 18 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2020 and excludes 28,050 shares previously owned directly which were contributed to the Estony McKeon Family, LLC on August 21, 2020.
(2)	Represents the weighted average price of the shares sold ranging from a low of $466.36 to a high of $467.31 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(3)	Represents the weighted average price of the shares sold ranging from a low of $467.38 to a high of $468.38 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(4)	Represents the weighted average price of the shares sold ranging from a low of $468.39 to a high of $469.39 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(5)	Represents the weighted average price of the shares sold ranging from a low of $469.40 to a high of $470.37 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(6)	Represents the weighted average price of the shares sold ranging from a low of $470.43 to a high of $471.43 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(7)	Represents the weighted average price of the shares sold ranging from a low of $471.44 to a high of $472.34 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(8)	Represents the weighted average price of the shares sold ranging from a low of $472.46 to a high of $473.46 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(9)	Represents the weighted average price of the shares sold ranging from a low of $473.5275 to a high of $474.46 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(10)	Represents the weighted average price of the shares sold ranging from a low of $474.63 to a high of $475.63 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(11)	Represents the weighted average price of the shares sold ranging from a low of $475.70 to a high of $476.51 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(12)	Represents the weighted average price of the shares sold ranging from a low of $476.785 to a high of $477.25 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(13)	Represents the weighted average price of the shares sold ranging from a low of $479.14 to a high of $480.135 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(14)	Represents the weighted average price of the shares sold ranging from a low of $480.17 to a high of $480.53 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
(15)	Grant of option to buy 18,108 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
(16)	Not applicable.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
MCKEON BRIAN P ONE IDEXX DRIVE WESTBROOK, ME 04092			Executive VP & CFO